Individuals

How do you know if your immune system is “fit” enough?
Are you vulnerable to suffering a poor health outcome if you were to develop an acute inflammatory condition such as COVID?
If you have a genetic susceptibility for a chronic inflammatory disease how do you know if you are actually developing it?
These are important questions for your long-term health. You could answer them then take proactive action to improve your health if you could detect and track the chronic inflammatory processes that drive cID progression at an early stage of cID development.

Unfortunately, you cannot use ordinary inflammation biomarkers such as hsCRP and cytokines (e.g. Tumour Necrosis Factor and IL-6) to answer these questions. Those tests measure big acute inflammation (aI) signals that accompany tissue damage and cannot measure the small cI signals that exist before tissue damage. Also, they cannot distinguish between chronic and acute inflammatory processes which is important to do when tracking cIDs.

Our GlyHealth-Index (GHI) test addresses the problem of chronic inflammation tracking. GHI allows you to monitor your level of chronic inflammation (cI) by analysing biomolecular patterns from a small sample (0.2ml) of your blood. It reliably measures chronic inflammation levels over a wide range of immune fitness levels – so it works whether you are superbly fit as well as if were someone with chronic health concerns.

This means that GHI can give you an early warning of increases in your cI (which could signal cID development) so you have time to take proactive action with an anti-inflammatory regime tailored to your particular needs.

GHI is easy to use and commercially available now.

Individuals

How do you know if your immune system is “fit” enough?
Are you vulnerable to suffering a poor health outcome if you were to develop an acute inflammatory condition such as COVID?
If you have a genetic susceptibility for a chronic inflammatory disease how do you know if you are actually developing it?
These are important questions for your long-term health. You could answer them then take proactive action to improve your health if you could detect and track the chronic inflammatory processes that drive cID progression at an early stage of cID development.

Unfortunately, you cannot use ordinary inflammation biomarkers such as hsCRP and cytokines (e.g. Tumour Necrosis Factor and IL-6) to answer these questions. Those tests measure big acute inflammation (aI) signals that accompany tissue damage and cannot measure the small cI signals that exist before tissue damage. Also, they cannot distinguish between chronic and acute inflammatory processes which is important to do when tracking cIDs.

Our GlyHealth-Index (GHI) test addresses the problem of chronic inflammation tracking. GHI allows you to monitor your level of chronic inflammation (cI) by analysing biomolecular patterns from a small sample (0.2ml) of your blood. It reliably measures chronic inflammation levels over a wide range of immune fitness levels – so it works whether you are superbly fit as well as if were someone with chronic health concerns.

This means that GHI can give you an early warning of increases in your cI (which could signal cID development) so you have time to take proactive action with an anti-inflammatory regime tailored to your particular needs.

GHI is easy to use and commercially available now.

Individuals

How do you know if your immune system is “fit” enough?
Are you vulnerable to suffering a poor health outcome if you were to develop an acute inflammatory condition such as COVID?
If you have a genetic susceptibility for a chronic inflammatory disease how do you know if you are actually developing it?
These are important questions for your long-term health. You could answer them then take proactive action to improve your health if you could detect and track the chronic inflammatory processes that drive cID progression at an early stage of cID development.

Unfortunately, you cannot use ordinary inflammation biomarkers such as hsCRP and cytokines (e.g. Tumour Necrosis Factor and IL-6) to answer these questions. Those tests measure big acute inflammation (aI) signals that accompany tissue damage and cannot measure the small cI signals that exist before tissue damage. Also, they cannot distinguish between chronic and acute inflammatory processes which is important to do when tracking cIDs.

Our GlyHealth-Index (GHI) test addresses the problem of chronic inflammation tracking. GHI allows you to monitor your level of chronic inflammation (cI) by analysing biomolecular patterns from a small sample (0.2ml) of your blood. It reliably measures chronic inflammation levels over a wide range of immune fitness levels – so it works whether you are superbly fit as well as if were someone with chronic health concerns.

This means that GHI can give you an early warning of increases in your cI (which could signal cID development) so you have time to take proactive action with an anti-inflammatory regime tailored to your particular needs.

GHI is easy to use and commercially available now.